Prospective signal study of Imetelstat in patients with refractory anemia with ring sideroblasts with (RARS-T) or without (RARS) thrombocytosis

Trial Profile

Prospective signal study of Imetelstat in patients with refractory anemia with ring sideroblasts with (RARS-T) or without (RARS) thrombocytosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Sideroblastic anaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 25 Feb 2016 According to a Geron Corporation media release, results for safety and efficacy from this study were presented at the 57th American Society of Hematology annual meeting.
    • 10 Nov 2015 According to a Geron Corporation media release, results from this study will be presented at the 57th American Society of Hematology annual meeting
    • 09 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top